PipelineReview.com - CAR T-Cells & NK Cells

Show Cart

CAR T-Cells & NK Cells

Results 1 - 3 of 3

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

(Discount: 33.33%)

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

Mar 2015 Engineered TCR and CAR Immunotherapeutics 2015

(Discount: 20.00%)

Currencies

Shopping cart

Cart empty

Latest report

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Latest Target Pipeline

Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018

Currencies

Shopping cart

Cart empty

Latest report

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Latest Target Pipeline

Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing